BioSpace
APRIL 1, 2021
One of the common research approaches to treating brain diseases such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) is using antibodies designed to clear the accumulated misfolded proteins implicated in the diseases. To date, these drug trials have not been particularly successful at i.
Drug Discovery World
MARCH 29, 2023
This is measured by changes in laboratory values including C-reactive protein and faecal calprotectin, and changes in validated clinical and endoscopic scoring systems. The post First patient dosed in ulcerative colitis drug trial appeared first on Drug Discovery World (DDW).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JUNE 9, 2023
The top stories: Successful Phase I results for cardioprotective drug Serca Pharmaceuticals has presented data on a novel approach to modulate the beta-adrenergic receptor-cAMP protein kinase A (PKA) signalling pathway that modulates the contractility.
Drug Discovery World
NOVEMBER 29, 2023
Mapping individual Alzheimer’s disease progression The team’s model relies on clinical biomarkers for Alzheimer’s disease, including fluid markers for the amyloid protein that is responsible for plaque build-up in the brain, cognitive decline scores from pencil-and-paper testing, and MRI brain images.
XTalks
APRIL 26, 2021
Given the success of Oxford’s Phase II trial, the study investigators are now gearing up for a Phase III licensure trial to assess large-scale safety and efficacy in 4,800 children aged 5 to 36 months across four countries in Africa. Malaria Vaccine Phase II Trial.
Drug Discovery World
MARCH 7, 2023
She founded Neuroute in 2019, with the aim of empowering patients from diverse backgrounds to participate in drug trials. She joined Novo Nordisk in 1997 and has held various scientific and leadership positions within Protein Engineering Research and Biopharmaceuticals.
Drug Discovery World
JANUARY 17, 2024
Moreover, NGS testing is being used in three main clinical circumstances, including: (i) the determination of patient eligibility for clinical trials, (ii) for guiding advanced refractory disease treatment when first line treatments have failed, and (iii) for off-label use of FDA-approved drugs.
Expert insights. Personalized for you.
73 
Let's personalize your content